Company research
ARROWHEAD PHARMACEUTICALS, INC.
CIK 879407Updated Nov 13, 2026
SecurityARWR · NASDAQ · equity
Name history
ARROWHEAD RESEARCH CORP · through Apr 6, 2016INTERACTIVE GROUP INC · through Jan 9, 2004INTERACTIVE INC · through Feb 13, 2002
ARWR price & chart
Loading TradingView…
NASDAQ:ARWR on TradingView ↗About the company
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry- leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
In the news
Recent filings
10-K filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by FMR LLC regarding ARROWHEAD PHARMACEUTICALS, INC.
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,112,013,000Source | 1,380,612,000Source | 883,759,000Source | 2,268,265,000Source | 1,573,498,000Source | 955,150,000Source | 1,604,181,000Source | 1,013,694,000Source | 1,385,295,000Source | 1,139,802,000Source | 765,552,000Source | 691,939,000Source |
| Property, Plant and Equipment, NetUSD | 373,301,000Source | 381,048,000Source | 375,911,000Source | 374,822,000Source | 384,803,000Source | 359,252,000Source | 378,584,000Source | 387,069,000Source | 382,515,000Source | 386,032,000Source | 290,262,000Source | 110,297,000Source |
| Current assets: | ||||||||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,556,000Source | 9,699,000Source | 0Source | 15,685,000Source | 2,365,000Source | 0Source | 218,871,000Source | 2,500,000Source | 6,824,000Source | 0Source | 0Source | 1,410,000Source |
| Assets, CurrentUSD | 1,671,411,000Source | 946,923,000Source | 450,062,000Source | 1,839,751,000Source | 1,135,220,000Source | 541,650,000Source | 1,174,389,000Source | 570,536,000Source | 950,639,000Source | 695,471,000Source | 419,521,000Source | 405,299,000Source |
| Operating Lease, Right-of-Use AssetUSD | 55,667,000Source | 44,002,000Source | 44,339,000Source | 42,794,000Source | 44,452,000Source | 44,626,000Source | 43,361,000Source | 44,869,000Source | 43,891,000Source | 45,255,000Source | 45,297,000Source | 58,291,000Source |
| Other Assets, NoncurrentUSD | 6,048,000Source | 1,353,000Source | 4,460,000Source | 4,887,000Source | 1,312,000Source | 210,000Source | 1,411,000Source | 3,083,000Source | 1,389,000Source | 4,482,000Source | 210,000Source | 218,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 237,000Source | 230,000Source | 217,000Source | 236,000Source | 230,000Source | 217,000Source | 233,000Source | 218,000Source | 231,000Source | 217,000Source | 200,000Source | 198,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,923,355,000Source | -1,603,404,000Source | -1,454,987,000Source | -1,729,075,000Source | -1,428,163,000Source | -1,284,194,000Source | -1,596,343,000Source | -1,798,608,000Source | -1,627,154,000Source | -1,625,523,000Source | -1,026,030,000Source | -820,755,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,234,000Source | 5,357,000Source | -987,000Source | 742,000Source | 4,390,000Source | -1,095,000Source | 6,699,000Source | 4,137,000Source | 6,443,000Source | 4,750,000Source | -3,222,000Source | -136,000Source |
| Stockholders' Equity Attributable to ParentUSD | 465,529,000Source | 522,313,000Source | 330,547,000Source | 613,977,000Source | 683,321,000Source | 483,794,000Source | 568,422,000Source | 52,589,000Source | 466,052,000Source | 185,444,000Source | 271,343,000Source | 398,520,000Source |
| Additional Paid in Capital, Common StockUSD | 2,443,074,000Source | 2,120,130,000Source | 1,786,304,000Source | 2,395,267,000Source | 2,106,864,000Source | 1,768,866,000Source | 2,211,026,000Source | 1,846,842,000Source | 2,139,725,000Source | 1,806,000,000Source | 1,300,395,000Source | 1,219,213,000Source |
| Liabilities and EquityUSD | 2,112,013,000Source | 1,380,612,000Source | 883,759,000Source | 2,268,265,000Source | 1,573,498,000Source | 955,150,000Source | 1,604,181,000Source | 1,013,694,000Source | 1,385,295,000Source | 1,139,802,000Source | 765,552,000Source | 691,939,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 283,346,000Source | 194,530,000Source | 96,714,000Source | 295,220,000Source | 220,541,000Source | 65,175,000Source | 347,425,000Source | 93,758,000Source | 195,487,000Source | 103,168,000Source | 105,456,000Source | 138,850,000Source |
| Operating Lease, Liability, CurrentUSD | 5,322,000Source | 7,010,000Source | 6,053,000Source | 7,774,000Source | 6,782,000Source | 5,285,000Source | 7,529,000Source | 6,560,000Source | 7,289,000Source | 6,342,000Source | 10,563,000Source | 2,776,000Source |
| Accounts Payable, CurrentUSD | 27,776,000Source | 33,050,000Source | 26,550,000Source | 30,747,000Source | 9,980,000Source | 8,521,000Source | 32,937,000Source | 14,457,000Source | 17,674,000Source | 11,388,000Source | 35,866,000Source | 2,868,000Source |
| Operating Lease, Liability, NoncurrentUSD | 114,298,000Source | 105,690,000Source | 112,040,000Source | 100,106,000Source | 107,529,000Source | 113,632,000Source | 102,129,000Source | 109,296,000Source | 104,112,000Source | 111,027,000Source | 104,608,000Source | 78,800,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 512,000Source | -2,507,000Source | 8,427,000Source | -15,061,000Source | 904,000Source | 11,611,000Source | -5,725,000Source | 3,486,000Source | 37,364,000Source | 5,619,000Source | 15,819,000Source | 19,819,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 86,174,000Source | 64,818,000Source | 47,899,000Source | 76,585,000Source | 78,450,000Source | 37,055,000Source | 130,081,000Source | 59,401,000Source | 90,419,000Source | 63,017,000Source | 39,763,000Source | 46,856,000Source |
| Cash and Cash Equivalents, at Carrying Value | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Dividends Payable, Current | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
| Short-term Investments | — | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -178,916,000Source | -178,652,000Source | -137,572,000Source | 367,863,000Source | 28,242,000Source | -175,218,000Source | 30,114,000Source | -609,693,000Source | -209,275,000Source | -176,494,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 6,200,000Source | 5,800,000Source | 5,900,000Source | 5,600,000Source | 6,000,000Source | 4,800,000Source | 22,200,000Source | 16,900,000Source | 10,700,000Source | 8,700,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 19,371,000Source | 15,209,000Source | 63,366,000Source | 73,968,000Source | 78,130,000Source | 120,893,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 212,046,000Source | 2,500,000Source | 56,967,000Source | 0Source | -1,410,000Source | -8,845,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 15,263,000Source | 3,069,000Source | 6,286,000Source | -5,536,000Source | 32,998,000Source | -6,589,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 13,481,000Source | -146,272,000Source | 179,552,000Source | -462,851,000Source | -153,890,000Source | -136,131,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -23,742,000Source | 76,910,000Source | -129,294,000Source | -420,072,000Source | -96,155,000Source | -5,417,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,148,000Source | 7,516,000Source | 22,666,000Source | 141,469,000Source | 176,737,000Source | 52,777,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -14,750,000Source | 20,634,000Source | 74,006,000Source | 870,520,000Source | 253,053,000Source | 65,186,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 54,759,000Source | 129,793,000Source | 188,517,000Source | 185,709,000Source | 201,643,000Source | 53,889,000Source | 226,548,000Source | 102,685,000Source | 110,891,000Source | 108,005,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 19,000Source | — | 0Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 9,907,000Source | 11,000Source | 814,000Source | -3,744,000Source | 0Source | -2,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 106,000Source | -68,000Source | -401,000Source | 4,197,000Source | -122,000Source | -67,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 14,974,000Source | 11,993,000Source | 16,568,000Source | 15,081,000Source | 19,590,000Source | 14,175,000Source | 54,848,000Source | 67,097,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -4,432,000Source |
| General and Administrative ExpenseUSD | — | — | — | 30,949,000Source | — | 28,405,000Source | 46,021,000Source | 26,910,000Source | 123,943,000Source | 98,761,000Source | 92,549,000Source | 124,431,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 11,000Source | -437,000Source | 7,000Source | 1,753,000Source | 29,000Source | 103,000Source | 21,419,000Source | -2,767,000Source | 2,784,000Source | 3,785,000Source |
| InterestExpenseNonoperatingUSD | — | — | 24,562,000Source | 24,382,000Source | 23,846,000Source | 21,639,000Source | 22,505,000Source | 21,646,000Source | 89,361,000Source | 32,352,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -194,280,000Source | -175,241,000Source | -132,732,000Source | 370,445,000Source | 30,811,000Source | -173,085,000Source | -1,631,000Source | -599,493,000Source | -205,275,000Source | -176,063,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 15,364,000Source | -3,411,000Source | -4,840,000Source | -2,582,000Source | -2,569,000Source | -2,133,000Source | 31,745,000Source | -10,200,000Source | -4,000,000Source | -431,000Source |
| Nonoperating Income (Expense)USD | — | — | -8,812,000Source | -13,539,000Source | 3,695,000Source | -11,586,000Source | -12,538,000Source | -13,703,000Source | -46,813,000Source | -11,380,000Source | -1,489,000Source | 5,798,000Source |
| Operating ExpensesUSD | — | — | 245,346,000Source | 193,317,000Source | 214,997,000Source | 161,507,000Source | 223,224,000Source | 163,912,000Source | 731,102,000Source | 604,631,000Source | 445,737,000Source | 421,738,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,285,000Source | -176,000Source | -1,609,000Source | 438,000Source | 277,000Source | 341,000Source | 5,259,000Source | -1,748,000Source | 1,538,000Source | 765,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 136,933,000Source | 33,749,000Source | 796,258,000Source | 720,947,000Source | 246,141,000Source | 223,391,000Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 60,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 46,832,000Source | 0Source | 241,388,000Source | 429,265,000Source | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,098,000Source | 634,000Source | 3,983,000Source | 2,389,000Source | 3,053,000Source | 5,186,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 19,000Source | 0Source | 0Source | -80,000Source | — | — |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Dividends Payable, Current | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Equity Method Investments | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 75,253,000Source | 27,767,000Source | 73,737,000Source | 542,709,000Source | 264,033,000Source | 2,500,000Source | 829,448,000Source | 3,551,000Source | 240,735,000Source | 243,231,000Source |
| Operating Income (Loss)USD | — | — | -170,093,000Source | -165,550,000Source | -141,260,000Source | 381,202,000Source | 40,809,000Source | -161,412,000Source | 98,346,000Source | -601,080,000Source | -205,002,000Source | -178,507,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,285,000Source | -176,000Source | -1,609,000Source | 438,000Source | 277,000Source | 341,000Source | 5,259,000Source | -1,748,000Source | 1,538,000Source | 765,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -178,905,000Source | -179,089,000Source | -137,565,000Source | 369,616,000Source | 28,271,000Source | -175,115,000Source | 51,533,000Source | -612,460,000Source | -206,491,000Source | -172,709,000Source |
| Income Tax Expense (Benefit)USD | — | — | 11,000Source | -437,000Source | 7,000Source | 1,753,000Source | 29,000Source | 103,000Source | 21,419,000Source | -2,767,000Source | 2,784,000Source | 3,785,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 15,364,000Source | -3,411,000Source | -4,840,000Source | -2,582,000Source | -2,569,000Source | -2,133,000Source | 31,745,000Source | -10,200,000Source | -4,000,000Source | -431,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -194,280,000Source | -175,241,000Source | -132,732,000Source | 370,445,000Source | 30,811,000Source | -173,085,000Source | -1,631,000Source | -599,493,000Source | -205,275,000Source | -176,063,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.36Source | -1.26Source | -0.93Source | 2.78Source | 0.22Source | -1.39Source | -0.01Source | -5Source | -1.92Source | -1.67Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.36Source | -1.26Source | -0.93Source | 2.75Source | 0.22Source | -1.39Source | -0.01Source | -5Source | -1.92Source | -1.67Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 143,378,000Source | 139,039,000Source | 142,417,000Source | 133,363,000Source | 137,039,000Source | 124,848,000Source | 133,758,000Source | 119,784,000Source | 106,750,000Source | 105,426,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 143,378,000Source | 139,039,000Source | 142,417,000Source | 134,484,000Source | 140,706,000Source | 124,848,000Source | 133,758,000Source | 119,784,000Source | 106,750,000Source | 105,426,000Source |
| Interest Expense (non-operating)USD | — | — | 24,562,000Source | 24,382,000Source | 23,846,000Source | 21,639,000Source | 22,505,000Source | 21,646,000Source | 89,361,000Source | 32,352,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 21,419,000Source | -2,767,000Source | 2,784,000Source | 3,785,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 6,390,000Source | 5,235,000Source | 23,928,000Source | 18,595,000Source | 12,493,000Source | 10,421,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -4,432,000Source |
| General and Administrative ExpenseUSD | — | — | — | 30,949,000Source | — | 28,405,000Source | 46,021,000Source | 26,910,000Source | 123,943,000Source | 98,761,000Source | 92,549,000Source | 124,431,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | 51,533,000Source | -612,460,000Source | -202,491,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -42,573,000Source | -582,333,000Source | -194,639,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 18,326,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 5,033,000Source |
| Nonoperating Income (Expense)USD | — | — | -8,812,000Source | -13,539,000Source | 3,695,000Source | -11,586,000Source | -12,538,000Source | -13,703,000Source | -46,813,000Source | -11,380,000Source | -1,489,000Source | 5,798,000Source |
| Operating ExpensesUSD | — | — | 245,346,000Source | 193,317,000Source | 214,997,000Source | 161,507,000Source | 223,224,000Source | 163,912,000Source | 731,102,000Source | 604,631,000Source | 445,737,000Source | 421,738,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 19,000Source | 0Source | 0Source | -80,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 198,223,000Source | 162,368,000Source | 173,253,000Source | 133,102,000Source | 177,203,000Source | 137,002,000Source | 607,159,000Source | — | — | — |
| Selling, General and Administrative Expense | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Equity Method Investments | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
Filing attachments
arwr-202611128kex991.htm · 8-K · 2026-11-12
EXHIBIT 99.1 PRESS RELEASE Nov. 12, 2026 Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET PASADENA, Calif., Nov. 12, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead has fundamentally changed over the p…
Read attachment ↗arwr-202611048kex991.htm · 8-K · 2026-11-04
EXHIBIT 99.1 PRESS RELEASE November 4, 2026 Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity - Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount - New $400 million term loan priced at SOFR plus 5.50% - Debt has no scheduled amortization payments or required sweeps during the term prior to the Maturity Date of November 2, 2031 PASADENA, Calif., November 4, 2026 - Arrowhe…
Read attachment ↗arwr-202608048kex991.htm · 8-K · 2026-08-04
EX-99.1 2 arwr-202608048kex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE August 4, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET PASADENA, Calif., August 4, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss …
Read attachment ↗arwr-202605078kex991.htm · 8-K · 2026-05-07
EX-99.1 2 arwr-202605078kex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE May 7, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results Conference Call and Webcast Today, May 7, 2026 at 4:30 p.m. ET PASADENA, Calif., May 7, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the resul…
Read attachment ↗arwr-202602058kex991.htm · 8-K · 2026-02-05
EXHIBIT 99.1 PRESS RELEASE February 5, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results Conference Call and Webcast Today, February 5, 2026 at 4:30 p.m. ET PASADENA, Calif., February 5, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results. “We had another quarter of stro…
Read attachment ↗d19865dex41.htm · 8-K · 2026-01-12
EX-4.1 2 d19865dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version ARROWHEAD PHARMACEUTICALS, INC. Debt Securities Indenture Dated as of January 12, 2026 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) …
Read attachment ↗